Risk factors
AbCellera Biologics (ABCL) risk factors
Item 1A of every AbCellera Biologics Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors97 risks11 new12 dropped37 reworded
AbCellera reports continued net losses of $146.4 million in 2025 and $162.9 million in 2024. The filing highlights increased focus on platform scalability, partner reliance, and AI-related security risks.
Filed Feb 24, 2026 - FY2024 10-K risk factors98 risks
AbCellera relies heavily on unproven antibody discovery platforms and early-stage therapeutics pipelines with no commercial products yet.
Filed Feb 27, 2025